DarioHealth Corp. DRIO

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus Nasdaq

We are a vertically integrated health intelligence platform with a mission to power the behavior changes that drive better health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, AI built on that proprietary data, and a behavior change and coaching layer validated through over 100 peer-reviewed clinical studies. We are committed to transforming healthcare by delivering a comprehensive and highly engaging whole-person health platform, which enables us to create a future where healthy change is effortless and accessible to all.

At the core of our mission and vision is engagement. We believe that most existing digital health solutions in the market fail to deliver improved health outcomes because users are not engaged due to a lack relevance, personalization, consumerization, and longitudinal data and information. We, and our acquired companies, first commercialized our digital behavioral health products in the direct-to-consumer ("D2C") marketplace, and we continue to use the D2C marketplace as a sandbox and laboratory to innovation. These consumers pay for these digital health products out of their own pockets and are therefore the most value driven among all healthcare consumers. These consumers demanded that we deliver highly engaging user experiences that deliver strong clinical health outcomes for which consumers will pay. The bottom line is that if users are not engaged in digital solutions over a long period of time, they cannot change their behavior and they cannot get healthier – we first deliver engagement followed by sustained behavior change that then leads to measurable health outcomes and improvement. We believe that our D2C marketplace roots and continued focus delivers better user experiences, longer sustained engagement, stronger clinical outcomes, at the most affordable prices, that then delivers the highest return on investment ("ROI") in the industry.

Last close 7.24 2026-09-04
Market cap $70.9M 2026-06-30 share count
52-week range 5.84 - 17.74

Valuation FY2025 figures against the last close

P/S3.2x
P/E0.7x
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS10.12

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $22.4M$27.0M$20.4M$27.7M$20.5M$7.6M$7.6M$7.4M$5.2M$2.8M
Cost of revenue $9.7M$13.8M$14.4M$18.0M$16.6M$5.1M$5.0M$5.6M$3.9M$3.4M
Gross profit $12.7M$13.3M$6.0M$9.7M$4.0M$2.5M$2.6M$1.8M$1.3M-$830.0K
R&D $13.8M$24.2M$20.2M$19.6M$17.2M$4.4M$3.7M$3.7M$3.3M$2.2M
SG&A $15.2M$20.5M$18.1M$16.5M$23.5M$12.8M$5.5M$5.5M$4.7M$3.4M
Total operating expenses $49.3M$71.0M$62.2M$66.5M$80.5M$32.4M$20.3M$19.5M$15.7M$10.3M
Operating income -$36.7M-$57.7M-$56.2M-$56.8M-$76.5M-$29.9M-$17.7M-$17.7M-$14.4M-$11.1M
Interest expense $3.0M
Pre-tax income -$41.6M-$44.6M-$59.4M-$62.2M-$76.7M-$29.4M-$17.7M-$17.8M-$15.7M-$10.9M
Income tax $105.0K$1.9M$64.0K$4.0K$32.0K
Net income -$41.7M-$42.7M-$59.4M-$62.2M-$76.8M-$29.4M-$17.7M-$17.8M-$15.7M-$10.9M
EPS, basic 10.1212.271.932.544.074.01
EPS, diluted 10.1212.271.932.544.074.018.0015.631.642.09
Shares, diluted (wtd. avg.) $4.0M$2.5M$28.4M$23.6M$16.6M$6.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $21.8M$27.8M$36.8M$49.5M$35.9M$28.7M$20.5M$11.1M$3.9M$1.1M
Short-term investments $258.0K$225.0K
Receivables $0
Inventory $4.3M$4.8M$5.1M$8.0M$6.2M$2.3M$1.4M$1.4M$1.2M$888.0K
Total current assets $35.1M$40.5M$47.3M$65.5M$45.6M$34.1M$22.9M$13.1M$6.0M$2.9M
Property, plant and equipment $549.0K$709.0K$899.0K$788.0K$702.0K$576.0K$648.0K$733.0K$869.0K$901.0K
Goodwill $57.4M$57.4M$41.6M$41.6M$41.6M$0
Other intangibles $15.9M$18.8M$5.4M$9.9M$12.5M
Total assets $110.1M$118.9M$96.4M$119.2M$100.8M$35.4M$24.6M$14.1M$7.0M$3.9M
Short-term debt $5.5M$4.0M$8.8M$0
Total current liabilities $9.3M$16.6M$12.5M$19.4M$14.4M$7.0M$5.2M$5.2M$3.0M$2.9M
Long-term debt $30.7M$23.5M$24.6M$18.1M$0
Retained earnings -$452.1M-$390.3M-$349.4M-$285.9M-$222.0M-$143.2M-$110.1M-$89.3M-$71.0M-$55.0M
Total equity $67.9M$72.0M$58.1M$80.0M$85.5M$28.2M$18.9M$8.9M$3.9M-$6.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$25.9M-$38.6M-$30.4M-$47.8M-$50.4M-$17.7M-$15.7M-$11.5M-$10.6M-$8.4M
Depreciation and amortisation $307.0K$1.3M$473.0K$356.0K$282.0K$190.0K$183.0K$207.0K$195.0K$387.0K
Stock-based compensation $46.0K
Capital expenditure $142.0K$138.0K$584.0K$442.0K$261.0K$118.0K$98.0K$71.0K$195.0K$808.0K
Investing cash flow -$4.3M-$8.9M-$547.0K-$573.0K-$8.1M-$1.6M-$113.0K-$72.0K-$219.0K-$947.0K
Financing cash flow $24.3M$38.5M$18.3M$61.9M$65.8M$27.5M$25.2M$18.7M$13.5M$7.7M
Buybacks $134.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-031621.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
RMD RESMED INC $32.94B 21.9x 9.9%
MDLN Medline Inc. $31.35B 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%